The product is indicated for the prevention and treatment of internal and external parasitic infections in dogs.
Main Ingredients
Imidacloprid, Moxidectin
Character
This product is yellow to brownish yellow liquid.
Indications
The product is indicated for the prevention and treatment of internal and external parasitic infections in dogs. The product is indicated for the prevention and treatment of flea infections (Ctenocephalus felis), treatment of lice infections (Trichodelus Canis), treatment of ear mite infections (Pruritus auriculu), canine scabies (Sarcoptes scabies) and demodicidosis (Demodex Canis), treatment of vascular and gastrointestinal nematode infections (adults, immature adults and L4 stage larvae of Toxocephalus Canis, Canis Haemostoma and Ancylostoma Canis); Adult Toxocaris lionis and Trichocephalus vulgaris), prevention of cardiac filariasis (stage L3 and L4 larvae of Difilaria Canis), treatment of circulating microfilariae (Difilaria Canis). And can assist in the treatment of allergic dermatitis caused by fleas.
Strength
(1)0.4ml: midacloprid 40mg+Moxidectin10mg
(2)1.0ml:imidacloprid 100mg+Moxidectin 25mg
(3)2.5ml:imidacloprid 250mg+Moxidectin 62.5mg
(4)4.0ml:imidacloprid 400mg+Moxidectin 100mg
Packaging
(1)1 tube/box (2)3 tubes/box
Storage
Seal preservation
Shelf life
36 months
For external use: one dose, 0.1ml per 1kg of body weight for dogs. The drug is administered once a month during prevention or treatment. In order to prevent the dog from licking, the product can be dropped on the skin between the two shoulder blades on the back of the dog and the hip, which can be applied at 3 or 4 spots.
|
Dog weight (kg) |
Type of applicable product |
Volume (ml) |
Imidacloprid (mg/kg body weight) |
Moxidectin (mg/kg body weight) |
|
≤4kg |
Small dog |
0.4ml |
No less than 10 |
No less than 2.5 |
|
>4~10kg |
Medium dog |
1.0ml |
10~25 |
2.5~6.25 |
|
>10~25kg |
Large dog |
2.5ml |
10~25 |
2.5~6.25 |
|
>25~40kg |
Very large dogs |
4.0ml |
10~16 |
2.5~4 |
|
>40kg |
Use a combination of products with appropriate specifications |
|||
Prevention and treatment of flea infections：A single dose can prevent fleas from becoming reinfected for up to 4 weeks. Pupae already present in the environment can hatch in 6 weeks or more, depending on the local climate. In order to cut off the life history of fleas in the natural environment, the use of this product should be combined with environmental treatment.
Treat lice infections：A single dose, 30 days after the administration of the veterinarian evaluation to determine whether a second dose is necessary.
Treat ear mite infections：For single administration, the ear debris in the external ear canal should be removed before administration. The need for a second dose should be determined 30 days after a veterinary examination and evaluation.
Treatment of sarcoptes scabies infections：The drug should be administered every 4 weeks, and a second dose should be administered.
Treatment of demodex infections：Dosing once every 4 weeks for 2 to 4 months can effectively prevent the occurrence of canine demodex and improve clinical symptoms significantly；For severe infections that may require longer and more frequent treatment, this product can be used once a week for a longer period of time depending on veterinary examination. In all cases, treatment should be continued until at least 2 consecutive months of skin dandruff is normal. Dogs that do not improve or the number of mites does not decrease after two months of treatment should be discontinued and given other medications under the guidance of a veterinarian. Because demodicidosis is a multifactorial disease, the underlying disease should be treated if possible.
Treatment of angiostrongylus infections：A single dose, 30 days after the administration of the veterinarian evaluation to determine whether a second dose is necessary. Routine monthly administration in endemic areas can prevent angiostrongylasis and significant angiostrongylasis infection.
Treatment of circulating microfilariae：The drug should be administered once a month, and a second dose should be administered.
Antiparasitic drug
Pharmacodynamics Imidacloprid is a new generation of chloronicotinyl nitroguanidine insecticide, which has high affinity to the post-synaptic nicotinic acetylcholine receptors in the central nervous system of insects, and can inhibit the activity of acetylcholine, resulting in parasite paralysis and death. It is effective against adult fleas and young fleas at all stages, and also has killing effect on young fleas in the environment. The action mechanism of moxidectin is similar to that of avermectin and ivermectin, and it has good repels and kills in vivo and in vitro parasites, especially nematodes and arthropods. The mechanism of its repellent action is to promote the release of neurotransmitter γ-aminobutyric acid (GABA), increase its binding force with postsynaptic receptors, and open chloride ion channels. Moxidectin also has selectivity and high affinity for glutamate-mediated chloride ion channels, which interferes with the signal transmission between neuromuscles, relaxes and paralyzes the worms, and leads to the death of the worms. Inhibitory interneurons and excitatory motor neurons are the sites of action in nematodes, while the sites of action in arthropods are neuromuscular junctions. The combination of the two has a synergistic effect.
Pharmacokinetics After initial administration, imidacloprid rapidly distributed to the canine body surface on the same day and remained on the body surface throughout the interadministration period. From 4 to 9 days after administration, the blood concentration of moxidectin in dogs reached the highest, and was distributed throughout the body and metabolized slowly within one month.
Adverse reactions
1. This product can cause transient itching, animals occasionally (<1/10000< incidence <10/10000) hair adhesion, erythema, or vomiting, these symptoms can disappear without treatment. The use of this product in animals may occasionally cause local allergic reactions.
2. After administration, if the animal licks the administration site, very few (<1/10000) may experience transient neurological symptoms, such as excitement, tremor, ophthalmic symptoms (dilated pupils, reduced pupil reflexes, and nystagmus), abnormal breathing, salivation, and vomiting; very rarely, transient behavioral changes such as reluctance to exercise, excitement, and loss of appetite may occur.
3. Field trials have shown that heartworm positive dogs with microfilariaemia are at risk of developing severe respiratory symptoms (cough, shortness of breath and dyspnea) and may require immediate veterinary treatment. Gastrointestinal symptoms (vomiting, diarrhea, loss of appetite) and drowsiness were also common in these dogs after use of this product.
Precautions
1. Do not use on dogs under 7 weeks of age. Do not use on dogs allergic to this product and excipients. This product has not been evaluated for safety in pregnant and lactating dogs, and veterinary advice should be followed before use.
2. Dogs under 1kg should follow veterinary advice when using this product.
3. Do not use this product on dogs with grade 4 heart filariasis as its safety has not been assessed in this fauna; only the safety of this product was assessed against grade 1 or 2 in dogs in laboratory studies and a small number of grade 3 cardiac filariasis in field trials. Therefore, for dogs with obvious or severe symptoms of heart filariasis, a risk assessment should be carried out when using.
4. Although it has been shown in overdose studies to be potentially safe in dogs infected with adult heartworm, it has no therapeutic effect on adult heartworm. Therefore, dogs 6 months of age and older living in canine difilarial endemic areas are recommended to be checked for adult heartworm infection before using this product. It is up to the veterinarian to decide if adult insecticide is needed. The safety of this product has not been evaluated for the same day of application of adult insecticide.
5. This product contains moxidectin (macrolides), so when using this product on Collies, Old English sheepdogs and related breeds, special care should be taken to prevent these dogs from licking this product orally.
6. Follow veterinary advice when using on sick and weak dogs.
7. Do not use this product on cats.
8. During the use of this product, do not allow the drug in the tube to come into contact with the eyes and mouth of the animal being administered or other animals. Keep animals from licking each other's fur after they are administered. Do not touch or trim the hair before the medicine has dried.
9. Occasional 1 or 2 exposures to water during dosing do not significantly affect the efficacy of the drug. However, the dog's frequent use of shampoo for bathing or soaking in water may affect the effectiveness of the medication.
10. Keep this product out of the reach of children.
11. Storage do not exceed 30℃, do not exceed the expiry date.
12. Do not administer to persons allergic to this product. People allergic to this product should not administer this product.
13. During administration, users should avoid contact with skin, eyes and mouth, and do not eat, drink or smoke; Wash hands after administration. If accidentally splashed on the skin, wash immediately with soap and water; If accidentally splashed into eyes, rinse immediately with water. If symptoms do not improve, please consult a doctor with the instructions.
14. At present, there is no special remedy for this product; If ingested, oral activated charcoal can help detoxify.
15. The solvents in this product may contaminate materials such as leather, fabric, plastic and painted surfaces. Prevent these materials from contacting the administration site until it is dry.
16. Do not allow this product to enter surface water.
17. Unused drugs and packaging materials should be treated harmlessly according to local requirements.
Withdrawal time
No customization required.
